Literature DB >> 23414799

Fluorinated N,N'-diarylureas as AMPK activators.

Vitaliy Sviripa1, Wen Zhang, Michael D Conroy, Eric S Schmidt, Alice X Liu, Johnny Truong, Chunming Liu, David S Watt.   

Abstract

Adenosine monophosphate-activated kinase (AMPK) plays a central role in regulating energy homeostasis in eukaryotic cells. AMPK also regulates lipid synthesis by inhibiting acetyl-CoA carboxylase (ACC) and regulates mTOR signaling by activating TSC2. Due to its important roles in cell metabolism, AMPK is an attractive target for metabolic diseases, such as type II diabetes and obesity. AMPK activators, such as metformin, that are used for diabetes treatment are also effective anticancer agents. However, the efficacies of many known AMPK activators are relatively low. For example, metformin activates AMPK at millimolar levels. In this study, we identified a novel family of AMPK activators, namely fluorinated N,N'-diarylureas, that activate AMPK at 1-3μM concentrations. These novel agents strongly inhibit the proliferation of colon cancer cells. We studied the potential mechanisms of these agents, performed a structure-activity relationship (SAR) study and identified several fluorinated N,N'-diarylureas as potent AMPK activators.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23414799      PMCID: PMC3594501          DOI: 10.1016/j.bmcl.2013.01.096

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.

Authors:  Brian I Carr; Aldo Cavallini; Catia Lippolis; Rosalba D'Alessandro; Caterina Messa; Maria G Refolo; Angela Tafaro
Journal:  J Cell Physiol       Date:  2013-02       Impact factor: 6.384

Review 2.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Authors:  Scott Wilhelm; Christopher Carter; Mark Lynch; Timothy Lowinger; Jacques Dumas; Roger A Smith; Brian Schwartz; Ronit Simantov; Susan Kelley
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

3.  In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.

Authors:  Séverine Denoyelle; Ting Chen; Limo Chen; Yibo Wang; Edvin Klosi; José A Halperin; Bertal H Aktas; Michael Chorev
Journal:  Bioorg Med Chem Lett       Date:  2011-11-16       Impact factor: 2.823

Review 4.  AMPK, the metabolic syndrome and cancer.

Authors:  Zhijun Luo; Asish K Saha; Xiaoqin Xiang; Neil B Ruderman
Journal:  Trends Pharmacol Sci       Date:  2005-02       Impact factor: 14.819

Review 5.  AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.

Authors:  Zhijun Luo; Mengwei Zang; Wen Guo
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

6.  Fluorinated N,N-dialkylaminostilbenes for Wnt pathway inhibition and colon cancer repression.

Authors:  Wen Zhang; Vitaliy Sviripa; Liliia M Kril; Xi Chen; Tianxin Yu; Jiandang Shi; Piotr Rychahou; B Mark Evers; David S Watt; Chunming Liu
Journal:  J Med Chem       Date:  2011-02-03       Impact factor: 7.446

7.  Role of AMP-activated protein kinase in mechanism of metformin action.

Authors:  G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

8.  The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Authors:  David B Shackelford; Reuben J Shaw
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 9.  AMPK activators--potential therapeutics for metabolic and other diseases.

Authors:  G Zhou; I K Sebhat; B B Zhang
Journal:  Acta Physiol (Oxf)       Date:  2009-02-19       Impact factor: 6.311

  9 in total
  8 in total

Review 1.  Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.

Authors:  Sandeep Rana; Elizabeth C Blowers; Amarnath Natarajan
Journal:  J Med Chem       Date:  2014-08-28       Impact factor: 7.446

2.  An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.

Authors:  Wen Zhang; Vitaliy M Sviripa; Liliia M Kril; Tianxin Yu; Yanqi Xie; W Brad Hubbard; Patrick G Sullivan; Xi Chen; Chang-Guo Zhan; Yang Yang-Hartwich; B Mark Evers; Brett T Spear; Roberto Gedaly; David S Watt; Chunming Liu
Journal:  J Med Chem       Date:  2019-12-16       Impact factor: 7.446

3.  Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells.

Authors:  Dasha E Kenlan; Piotr Rychahou; Vitaliy M Sviripa; Heidi L Weiss; Chunming Liu; David S Watt; B Mark Evers
Journal:  Mol Cancer Ther       Date:  2017-03-03       Impact factor: 6.261

4.  Pentafluorosulfanyl-containing Triclocarban Analogs with Potent Antimicrobial Activity.

Authors:  Eugènia Pujol; Núria Blanco-Cabra; Esther Julián; Rosana Leiva; Eduard Torrents; Santiago Vázquez
Journal:  Molecules       Date:  2018-11-02       Impact factor: 4.411

5.  Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.

Authors:  Jeremy Johnson; Piotr Rychahou; Vitaliy M Sviripa; Heidi L Weiss; Chunming Liu; David S Watt; B Mark Evers
Journal:  PLoS One       Date:  2019-03-15       Impact factor: 3.240

6.  Novel chemotherapeutic agent, FND-4b, activates AMPK and inhibits colorectal cancer cell proliferation.

Authors:  Heather F Sinner; Jeremy Johnson; Piotr G Rychahou; David S Watt; Yekaterina Y Zaytseva; Chunming Liu; B Mark Evers
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

7.  In Vitro, In Vivo, and Absorption, Distribution, Metabolism, and Excretion Evaluation of SF5-Containing N,N'-Diarylureas as Antischistosomal Agents.

Authors:  Alexandra Probst; Eugènia Pujol; Cécile Häberli; Jennifer Keiser; Santiago Vázquez
Journal:  Antimicrob Agents Chemother       Date:  2021-07-26       Impact factor: 5.191

Review 8.  Modulation of Autophagy by Sorafenib: Effects on Treatment Response.

Authors:  Nestor Prieto-Domínguez; Raquel Ordóñez; Anna Fernández; Andres García-Palomo; Jordi Muntané; Javier González-Gallego; José L Mauriz
Journal:  Front Pharmacol       Date:  2016-06-08       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.